141 related articles for article (PubMed ID: 34089852)
1. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.
Park J; Le AK; Tseng TC; Yeh ML; Jun DW; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung KS; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
Clin Gastroenterol Hepatol; 2022 Apr; 20(4):874-885.e4. PubMed ID: 34089852
[TBL] [Abstract][Full Text] [Related]
2. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
Liu M; Tseng TC; Jun DW; Yeh ML; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung M; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
Hepatol Int; 2021 Feb; 15(1):71-81. PubMed ID: 33394321
[TBL] [Abstract][Full Text] [Related]
3. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
5. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria.
Sinn DH; Kim SE; Kim BK; Kim JH; Choi MS
J Viral Hepat; 2019 Dec; 26(12):1465-1472. PubMed ID: 31332935
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.
Ungtrakul T; Mahidol C; Chun-On P; Laohapand C; Siripongsakun S; Worakitsitisatorn A; Vidhayakorn S; Boonchuay W; Dechma J; Sornsamdang G; Soonklang K; Sriprayoon T; Tanwandee T; Auewarakul CU
World J Gastroenterol; 2016 Sep; 22(34):7806-12. PubMed ID: 27678364
[TBL] [Abstract][Full Text] [Related]
7. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.
Li J; Yang HI; Yeh ML; Le MH; Le AK; Yeo YH; Dai CY; Barnett S; Zhang JQ; Huang JF; Trinh HN; Wong C; Wong C; Hoang JK; Cheung R; Yu ML; Nguyen MH
J Infect Dis; 2021 Jul; 224(2):294-302. PubMed ID: 33249474
[TBL] [Abstract][Full Text] [Related]
8. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
[TBL] [Abstract][Full Text] [Related]
9. Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B.
Huang DQ; Lee DH; Le MH; Le A; Yeo YH; Trinh HN; Chung M; Nguyen V; Johnson T; Zhang JQ; Wong C; Wong C; Li J; Cheung R; Nguyen MH
Dig Dis; 2023; 41(1):115-123. PubMed ID: 36070707
[TBL] [Abstract][Full Text] [Related]
10. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
[TBL] [Abstract][Full Text] [Related]
11. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
[TBL] [Abstract][Full Text] [Related]
12. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
13. Lower Observed Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Patients Treated With Entecavir: Results of the ENUMERATE Study.
Ahn J; Lim JK; Lee HM; Lok AS; Nguyen M; Pan CQ; Mannalithara A; Te H; Reddy KR; Trinh H; Chu D; Tran T; Lau D; Leduc TS; Min A; Trong Le L; Bae H; Van Tran S; Do S; Hann HW; Wong C; Han S; Pillai A; Park JS; Tong M; Scaglione S; Woog J; Kim WR
Am J Gastroenterol; 2016 Sep; 111(9):1297-304. PubMed ID: 27325221
[TBL] [Abstract][Full Text] [Related]
14. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma incidence in noncirrhotic patients with chronic hepatitis B and patients with cirrhosis of all etiologies.
Do AL; Wong CR; Nguyen LH; Nguyen VG; Trinh H; Nguyen MH
J Clin Gastroenterol; 2014 Aug; 48(7):644-9. PubMed ID: 24201999
[TBL] [Abstract][Full Text] [Related]
16. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
[TBL] [Abstract][Full Text] [Related]
18. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
19. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
20. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study.
Su MH; Lu AL; Li SH; Zhong SH; Wang BJ; Wu XL; Mo YY; Liang P; Liu ZH; Xie R; He LX; Fu WD; Jiang JN
World J Gastroenterol; 2015 Dec; 21(46):13087-94. PubMed ID: 26673249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
